key: cord-1022403-fbm0aag3
authors: Liu, Xiao; Long, Chuyan; Xiong, Qinmei; Chen, Chen; Ma, Jianyong; Su, Yuhao; Hong, Kui
title: Re: Is there a difference in the effect between the angiotensin‐converting enzyme inhibitor and angiotensin‐receptor blocker on the COVID‐19?
date: 2020-11-12
journal: Clin Cardiol
DOI: 10.1002/clc.23473
sha: 9f437588ab52dd1c8bc8b2c74421853bdfcf6d17
doc_id: 1022403
cord_uid: fbm0aag3

nan

F I G U R E 1 Summary of the associations between use of ACEI/ARB and clinical outcomes among patients with COVID-19 stratified by ACEI and ARB: A, risk of COVID-19 infection; B, risk of severe COVID-19 infection; C, mortality. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensinreceptor blockers

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry

Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients

Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: a rapid systematic review and meta-analysis

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study